Generic Name: halobetasol propionate and tazarotene
Brand Name: TBC
Manufacturer: Bausch Health, Canada Inc.
Therapeutic Area: Psoriasis, moderate to severe plaque
Indications: Psoriasis, moderate to severe plaque
Manufacturer Requested Reimbursement Criteria1: Topical treatment of moderate-to-severe plaque psoriasis.
Submission Type: Initial
Project Status: Withdrawn
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
|Call for patient input posted||January 07, 2019|
|Submission received||February 04, 2019|
- Voluntarily withdrawn by the manufacturer on 2019-Feb-19